K. Jameson
Nurix (United States)(US)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Nanoplatforms for cancer theranostics, Radiopharmaceutical Chemistry and Applications, HER2/EGFR in Cancer Research, Brain Metastases and Treatment
Most-Cited Works
- → IQGAP1 scaffold-kinase interaction blockade selectively targets RAS-MAP kinase–driven tumors(2013)199 cited
- → Genetic pathways in disorders of epidermal differentiation(2012)115 cited
- → Identification of novel and conserved functional and structural elements of the G1 cyclin Cln3 important for interactions with the CDK Cdc28 inSaccharomyces cerevisiae(2005)17 cited
- → A first-in-human phase 1 trial of nx-1607, a first-in-class oral CBL-B inhibitor, in patients with advanced solid tumor malignancies.(2022)12 cited
- → A phase I trial evaluating NBTXR3 activated by radiotherapy in combination with nivolumab or pembrolizumab in patients with advanced cancers.(2021)8 cited
- → 126TiP a Phase I Study of NBTXR3 Activated by Radiotherapy for Patients with Advanced Cancers Treated with an Anti-PD-1 Therapy(2019)5 cited
- → PB2099: A FIRST-IN-HUMAN PHASE 1 TRIAL OF NX-1607, A FIRST-IN-CLASS ORAL CBL-B INHIBITOR, IN PATIENTS WITH ADVANCED MALIGNANCIES INCLUDING RICHTER TRANSFORMATION DLBCL(2022)5 cited
- → P650: A FIRST-IN-HUMAN PHASE 1 TRIAL OF NX-5948, AN ORAL BTK DEGRADER, IN PATIENTS WITH RELAPSED AND REFRACTORY B-CELL MALIGNANCIES(2022)4 cited
- → NANORAY-1100: A phase I study of NBTXR3 activated by radiotherapy in patients with advanced cancers treated with anti-PD-1 therapy.(2020)4 cited
- → NBTXR3 Radiation Enhancing Hafnium Oxide Nanoparticles Activated By Radiotherapy In Combination With Anti-PD-1 Therapy: A Phase I Study(2020)4 cited